João A, Serrano P, Bártolo E, Neves A, Menezes BF

Idioma: Portugués
Referencias bibliográficas: 11
Paginas: 84-87
Archivo PDF: 239.59 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. 1.Glenner GG. Amyloid deposits and amyloidosis. The B-fibrilloses. N Engl J Med 1980;302:1283-92.

2. Breathnach SM. Amyloid and amyloidosis. J Am Acad Dermatol 1988;18:1-16.

3. 3.Falk RH, Comenzo RL, Skinner M. The Systemic Amyloidosis. N Engl J Med 1997;25:898-908.

4. Kois JM, Sexton FM, Lookingbill. Cutaneous Manifestations of Multiple Myeloma. Arch Dermatol 1991;127:69-74.

5. 5.Gutiérrez JV, Fernández MM, Sambucety PS, Valiente JS, Prieto MA. Med Cutan Iber Lat Am 2004;32:211-214.

6. 6.Solomon A, Frangione B, Franklin EC. Bence Jones proteins and light chains of immunoglobulins: preferential association of the V λ VI subgroup of human light chains with amyloidosis AL (l). J Clin Invest 1982;70:453-60.

7. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clin Proc 1983;58:665-83.

8. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59.

9. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-7.

10. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for treatment of AL amyloidosis: one year follow-up in five patients. Blood 1996;88:2801-6.

11. Dubrey SW, Mendes L, Skinner M, Falk RH. Resolution of heart failure in patients with AL amyloidosis. Ann Intern Med 1996;125:481-4.